Cost Drivers Report 2023
Annual cost growth in Canada’s private drug benefit market is driven by increased utilization and chronic disease drugs, with an increase in claimants post‑pandemic.
Read the full report.
All Resources
Our resource hub to discover reports, policy papers and other forms of informative content
Filter by
Two years is too long – Understanding Canada’s Drug Access Pathway
Canadians wait two years for access to new medicines through our public drug plans. That’s a full year longer than patients in most other peer countries. Two years can feel like a lifetime for a patient waiting for access to life-saving medicines or treatments.
Value of Medicines in Canada
This study examines and quantifies the value of innovative treatments in Canada to patient lives, the healthcare system and to society. Case studies include: HPV vaccines, Melanoma treatments, treatment for Rheumatoid Arthritis and Hepatitis C.
Developing a Canadian managed entry approach for new innovation: What can Canada learn from Europe?
Many new therapies coming to the market are not well served by the traditional drug reimbursement approaches currently employed by Canada’s public plans. A growing number of European regulatory authorities have been using novel managed entry agreements (MEA) and innovative access agreements (IAA) to accelerate approval times and improve availability to patients.
Clinical Trials in Canada
The innovative pharmaceutical industry has sponsored over two-thirds of clinical trials initiated in Canada in the last 5 years and contributed over $15 billion to the Canadian economy annually.
Innovative Access Arrangements and Managed Entry
A growing number of payers in many countries are looking to managed entry agreements (MEAs) and other innovative access arrangements (IAAs) to allow rapid access to medicines that address significant unmet needs.
Increasing Access to Innovative Medicines
The impact of the COVID-19 pandemic has shifted the health landscape in Canada. While the federal government has demonstrated its ability to react to an unprecedented health crisis, doing so has also sharpened the focus on domestic capacity and innovation in the life sciences sector.
Throughout the pandemic, we could not be prouder of our members’ collaborative efforts worldwide. From the onset, they worked toward agreements with nations and competitors to increase manufacturing capacity and minimize pharmaceutical supply chain disruption. IMC members demonstrated the industry’s value to the world, as the critical importance of reliable access to medicines was brought into focus.
Alberta Budget Submission 2023
Innovative Medicines Canada (IMC) is the national association representing Canada’s innovative pharmaceutical industry. The association advocates for policies that promote the discovery, development and delivery of innovative medicines and vaccines to improve the lives of all Canadians. In addition, it supports the commitment of its members as valued partners in the Canadian healthcare system.
The association represents 50 companies, which invest nearly $1.4 billion annually in research and development. In this way, it nurtures a high value-added knowledge economy while contributing $8 billion to the national economy.
